| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/24/2024 | $8.50 | Buy | Ascendiant Capital Markets |
Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to
Seek to clarify that certain hearing implants are prosthetics and therefore not subject to the hearing aid coverage exclusion, allowing for potential Medicare coverageWhite Bear Lake, Minnesota--(Newsfile Corp. - March 17, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced the reintroduction of the Hearing Device Coverage Clarification Act in both the U.S. House of Representatives and U.S. Senate. Representative Michelle Fischbach (R-MN) reintroduced the House version of the bill - H.R. 1921 - along with Representative Angie Craig (D-MN) on March 6, 2025. Senator Amy Klobuchar (D-MN)
Billionaire Entrepreneur Glen Taylor, the Company's Largest Shareholder, Continues to Invest Significant Capital into the Company Furthering Its ProgressWhite Bear Lake, Minnesota--(Newsfile Corp. - March 12, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced securing $10 Million in financing from its largest existing shareholder, billionaire entrepreneur Glen Taylor. The financing provides the Company with access to additional capital during what it expects to be a transformative year with several important milestones. The funds will be used to maintain the Company's velocity throug
White Bear Lake, Minnesota--(Newsfile Corp. - March 10, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced that it will participate in the 37th Annual ROTH Conference being held on March 16 - 18, 2025 at the Laguna Cliffs Marriott Resort and Spa in Dana Point, California.Brent Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer, will be holding one-on-one meetings with investors and analysts at the conference to discuss recent events and provide an update. Registered attendees of the conference are encouraged to request a one-on-one meeting by contacting a ROT
White Bear Lake, Minnesota--(Newsfile Corp. - February 24, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on providing hearing loss sufferers with innovative solutions today announces the successful enrollment of the first two participants in its pivotal clinical study. The purpose of the study is to investigate the safety and efficacy of the fully implanted Acclaim® cochlear implant and support its eventual premarket approval (PMA) application. If successful, the fully implanted Acclaim® cochlear implant could represent a paradigm shift in the cochlear implant industry and provide a significant business opportunity for Envoy Medical. "We are e
White Bear Lake, Minnesota--(Newsfile Corp. - February 14, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company focused on providing hearing loss sufferers with innovative solutions today announces additional patents for its growing patent portfolio. The US Patent & Trademark Office issued Envoy Medical Corporation US Pat. No. 12,214,195 on February 4, 2025. The title of the patent is Implantable Cochlear System with Inner Ear Sensor. This patent relates to cochlear implant systems having a cochlear electrode, a stimulator in electrical communication with the cochlear electrode, an inner ear sensor, and a signal processor in communication with the stimulator
Initial patient enrollment anticipated during first quarter of 2025White Bear Lake, Minnesota--(Newsfile Corp. - December 19, 2024) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company, today announces it has selected seven study sites for participation in its pivotal clinical trial to investigate its fully implanted Acclaim® cochlear implant (Acclaim CI). Initial patient enrollment is anticipated to begin during the first quarter of 2025. The Investigational Device Exemption (IDE) application for the pivotal study of the Acclaim® Fully Implanted Cochlear Implant was approved by the U.S. Food and Drug Administration (FDA) last month. The Acclaim CI is a fully impl
WHITE BEAR LAKE, Minnesota , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on providing hearing loss suffers with innovative solutions today announces four new patents. The US Patent & Trademark Office issued Envoy Medical Corporation US Pat. No. 12,151,102 on November 25, 2024. The title of the patent is Combination Hearing Aid and Cochlear Implant System. This patent relates to updating a transfer function associated with an implanted signal processor of a cochlear implant system to compensate for operation of an external auditory aid device, such as a hearing aid, that affects a stimulus received at an input
WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous
Study in Otology & Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear implant WHITE BEAR LAKE, Minnesota , Nov. 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces a peer-reviewed publication in Otology & Neurotology, discussing early experiences with and highlighting potential benefits of the Company's investigational fully implanted Acclaim® Cochlear Implant (Acclaim CI). The paper, titled, "Early Hearing Outcomes and Audiological Experiences with a Novel Fully Implanted Cochlear Implant," discusses the initial result
Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50
8-K - Envoy Medical, Inc. (0001840877) (Filer)
8-K - Envoy Medical, Inc. (0001840877) (Filer)
8-K - Envoy Medical, Inc. (0001840877) (Filer)
SCHEDULE 13G/A - Envoy Medical, Inc. (0001840877) (Subject)
424B5 - Envoy Medical, Inc. (0001840877) (Filer)
424B3 - Envoy Medical, Inc. (0001840877) (Filer)
8-K - Envoy Medical, Inc. (0001840877) (Filer)
424B3 - Envoy Medical, Inc. (0001840877) (Filer)
8-K - Envoy Medical, Inc. (0001840877) (Filer)
424B3 - Envoy Medical, Inc. (0001840877) (Filer)
Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to
WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous
Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year WHITE BEAR LAKE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the second quarter ended June 30, 2024. "We are pleased with the steady progress that Envoy Medical has made this quarter and year-to-date in advancing our goal of becoming a leading cochle
The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its "breakthrough" fully implanted cochlear implant. WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the first quarter ended March 31, 2024. Financial and Corporate Highlights from Q1 2024 All three participants in the ongoing Early Feasibility Study (EFS) at Mayo Clinic (Rochester, MN) have completed their 12-m
Company Provides Corporate Update that Include Updates on its Investigational Fully Implanted Acclaim® Cochlear Implant Meeting its Early Feasibility Study Milestones Recent bipartisan Congressional bill, the Hearing Device Coverage Clarification Act, seeks to open a pathway to insurance coverage for the Company's Esteem® Fully Implanted Active Middle Ear Implant WHITE BEAR LAKE, Minn., April 02, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2023. Financial and
Interim Findings from Early Feasibility Trial Provide Important Learnings and Feedback Ahead of Pivotal Clinical Trial Planned for 2024 Virtual Fireside Chat to be held December 7 WHITE BEAR LAKE, Minn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Envoy Medical, Inc. ("Envoy Medical") (NASDAQ:COCH), a hearing health company, today is providing a business update and its financial results for the quarter ended September 30, 2023. The Company will host a virtual fireside chat event on December 7, which will cover a range of topics, including introductions to the technology, financial and clinical aspects of the business, as well as potential participation from cochlear implant key opinion leader
WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently
Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
SC 13G - Envoy Medical, Inc. (0001840877) (Subject)
SC 13G - Envoy Medical, Inc. (0001840877) (Subject)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)
4 - Envoy Medical, Inc. (0001840877) (Issuer)